Camber Capital Management LP Clovis Oncology, Inc. Transaction History

Camber Capital Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$12.81 - $25.67 $19.2 Million - $38.5 Million	-1,500,000 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$17.66 - $30.28 $23 Million - $39.4 Million	-1,300,000 Reduced 46.43%	1,500,000 $37.2 Million
Q4 2018 Feb 14, 2019	BUY	$11.63 - $32.67 $12.2 Million - $34.3 Million	1,050,000 Added 60.0%	2,800,000 $50.3 Million
Q3 2018 Nov 14, 2018	BUY	$29.37 - $49.48 $22 Million - $37.1 Million	750,000 Added 75.0%	1,750,000 $51.4 Million
Q2 2018 Aug 14, 2018	BUY	$42.06 - $62.4 $7.36 Million - $10.9 Million	175,000 Added 21.21%	1,000,000 $45.5 Million
Q1 2018 May 15, 2018	BUY	$50.12 - $67.72 $11.3 Million - $15.2 Million	225,000 Added 37.5%	825,000 $43.6 Million
Q4 2017 Feb 14, 2018	BUY	$57.69 - $84.58 $23.1 Million - $33.8 Million	400,000 Added 200.0%	600,000 $40.8 Million
Q3 2017 Nov 14, 2017	BUY	$67.17 - $84.81 $13.4 Million - $17 Million	200,000	200,000 $16.5 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Camber Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Camber Capital Management LP with notifications on news.